Positive News Sentiment NASDAQ:AVXL Anavex Life Sciences - AVXL Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Anavex Life Sciences Corp. Please log in to your account or sign up in order to add this asset to your watchlist. $8.72 +0.04 (+0.46%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$8.42▼$8.7950-Day Range$8.52▼$11.7552-Week Range$7.13▼$15.24Volume1.08 million shsAverage Volume1.14 million shsMarket Capitalization$680.42 millionP/E RatioN/ADividend YieldN/APrice Target$41.80 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Anavex Life Sciences MarketRank™ ForecastAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside379.4% Upside$41.80 Price TargetShort InterestBearish20.92% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.80) to ($0.65) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.21 out of 5 starsMedical Sector372nd out of 1,005 stocksBiological Products, Except Diagnostic Industry65th out of 168 stocks 3.4 Analyst's Opinion Consensus RatingAnavex Life Sciences has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $41.80, Anavex Life Sciences has a forecasted upside of 379.4% from its current price of $8.72.Amount of Analyst CoverageAnavex Life Sciences has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted20.92% of the outstanding shares of Anavex Life Sciences have been sold short.Short Interest Ratio / Days to CoverAnavex Life Sciences has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Anavex Life Sciences has recently decreased by 4.73%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAnavex Life Sciences does not currently pay a dividend.Dividend GrowthAnavex Life Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAnavex Life Sciences has received a 73.63% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is mostly driven by its "Clinical research services for genetic diseases", "Preclinical research services for mental health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Anavex Life Sciences is -0.83. Previous Next 3.3 News and Social Media Coverage News SentimentAnavex Life Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Anavex Life Sciences this week, compared to 1 article on an average week.Search Interest44 people have searched for AVXL on MarketBeat in the last 30 days. This is an increase of 13% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added Anavex Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Anavex Life Sciences insiders have not sold or bought any company stock.Percentage Held by Insiders11.00% of the stock of Anavex Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.22% of the stock of Anavex Life Sciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Anavex Life Sciences are expected to grow in the coming year, from ($0.80) to ($0.65) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Anavex Life Sciences is -13.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Anavex Life Sciences is -13.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAnavex Life Sciences has a P/B Ratio of 4.77. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Anavex Life Sciences (NASDAQ:AVXL) StockAnavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.Read More Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AVXL Stock News HeadlinesMarch 17, 2023 | americanbankingnews.comAnavex Life Sciences (NASDAQ:AVXL) Coverage Initiated by Analysts at StockNews.comMarch 16, 2023 | markets.businessinsider.comBTIG Remains a Buy on Anavex Life Sciences (AVXL)March 25, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.March 15, 2023 | finance.yahoo.comWall Street Thinks This Small-Cap Stock Can Quadruple in ValueMarch 13, 2023 | finance.yahoo.comAcadia (ACAD) Gets FDA Approval for Daybue for Rett SyndromeMarch 9, 2023 | finance.yahoo.comAnavex Life Sciences Appoints Former FDA Lead Neurology Statistician as Vice President Head of BiostatisticsMarch 6, 2023 | finance.yahoo.comWhy Shares of Anavex Life Sciences Rose 12.4% in FebruaryFebruary 23, 2023 | finance.yahoo.comIs Anavex Life Sciences Stock a Buy Now?March 25, 2023 | Investor Place Media (Ad)Biden To Unleash "Choke Point" Operation On America?Biden's disturbing new government program may be worse than Obama's. You are at risk for having your bank account frozen. A former bank regulator is blowing the whistle on Biden's frightening plan to take over your money. Discover the immediate steps you need to take now.February 7, 2023 | finanznachrichten.deAnavex Life Sciences Corp.: Anavex Life Sciences Reports Fiscal 2023 First Quarter Financial ResultsFebruary 7, 2023 | finance.yahoo.comAnavex Life Sciences Reports Fiscal 2023 First Quarter Financial ResultsFebruary 2, 2023 | msn.comAnavex gains as trial for Rett syndrome candidate exceeds enrollment targetFebruary 2, 2023 | finance.yahoo.comAnavex Life Sciences Announces Exceeding of Enrollment Target for the ANAVEX®2-73 (blarcamesine) EXCELLENCE Phase 2/3 Rett Syndrome Clinical TrialJanuary 30, 2023 | thestreet.comAnavex Life Sciences (AVXL) Stock Soars on FDA GuidanceJanuary 30, 2023 | seekingalpha.comApproval For Anavex's Blarcamesine Looks Inevitable After Biogen's Leqembi ApprovedJanuary 20, 2023 | finance.yahoo.comFDA Rejects Accelerated Nod to Lilly's (LLY) Alzheimer's DrugJanuary 10, 2023 | msn.com$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 TodayDecember 29, 2022 | seekingalpha.comBiogen's Alzheimer's Drug Likely To Be Approved With Warning LabelsDecember 27, 2022 | msn.comHere's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth TodayDecember 21, 2022 | msn.comAnalyzing Anavex Life Sciences's Short InterestDecember 17, 2022 | finance.yahoo.comAnavex Life Sciences Stock Could 5x Before 2025 -- Here's WhyDecember 14, 2022 | finance.yahoo.comAnavex Strengthens Scientific Advisory Board with Investigator from Phase 2b/3 Alzheimer’s TrialDecember 8, 2022 | msn.comHere's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 YearsDecember 6, 2022 | seekingalpha.comAnavex Life Sciences: The Little Company That DidDecember 5, 2022 | finance.yahoo.comAnavex's (AVXL) Lead Alzheimer's Drug Meets Study GoalDecember 3, 2022 | markets.businessinsider.comBerenberg Bank Reaffirms Their Buy Rating on Anavex Life Sciences (AVXL)December 3, 2022 | finance.yahoo.comAnavex Life Sciences to Announce Management Webcast and Conference Call on Monday December 5, 2022See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AVXL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Anavex Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AVXL Company Calendar Last Earnings2/07/2023Today3/25/2023Next Earnings (Estimated)5/09/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVXL CUSIPN/A CIK1314052 Webwww.anavex.com Phone(844) 689-3939FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Forecast$41.80 High Stock Price Forecast$80.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+379.4%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.65) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,980,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-34.50% Return on Assets-32.22% Debt Debt-to-Equity RatioN/A Current Ratio11.20 Quick Ratio11.20 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.83 per share Price / Book4.77Miscellaneous Outstanding Shares78,030,000Free Float69,448,000Market Cap$680.42 million OptionableOptionable Beta0.75 Key ExecutivesChristopher U. MisslingChairman, President, CEO & SecretaryStephan ToutainChief Operating OfficerSandra BoenischChief Financial Officer & TreasurerWalter E. KaufmannChief Scientific OfficerEdward R. HammondChief Medical OfficerKey CompetitorsSana BiotechnologyNASDAQ:SANAImmunityBioNASDAQ:IBRXAllogene TherapeuticsNASDAQ:ALLOADMA BiologicsNASDAQ:ADMAExscientiaNASDAQ:EXAIView All CompetitorsInsiders & InstitutionsState of Wisconsin Investment BoardSold 4,699 shares on 2/15/2023Ownership: 0.094%Jane Street Group LLCBought 10,500 shares on 2/15/2023Ownership: 0.000%Alps Advisors Inc.Bought 10,424 shares on 2/15/2023Ownership: 0.068%Legal & General Group PlcBought 1,111 shares on 2/15/2023Ownership: 0.046%E Fund Management Co. Ltd.Bought 5,547 shares on 2/15/2023Ownership: 0.031%View All Insider TransactionsView All Institutional Transactions AVXL Stock - Frequently Asked Questions Should I buy or sell Anavex Life Sciences stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anavex Life Sciences in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AVXL shares. View AVXL analyst ratings or view top-rated stocks. What is Anavex Life Sciences' stock price forecast for 2023? 4 Wall Street analysts have issued 1-year price targets for Anavex Life Sciences' shares. Their AVXL share price forecasts range from $11.00 to $80.00. On average, they expect the company's share price to reach $41.80 in the next year. This suggests a possible upside of 379.4% from the stock's current price. View analysts price targets for AVXL or view top-rated stocks among Wall Street analysts. How have AVXL shares performed in 2023? Anavex Life Sciences' stock was trading at $9.26 at the beginning of 2023. Since then, AVXL shares have decreased by 5.8% and is now trading at $8.72. View the best growth stocks for 2023 here. When is Anavex Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 9th 2023. View our AVXL earnings forecast. How were Anavex Life Sciences' earnings last quarter? Anavex Life Sciences Corp. (NASDAQ:AVXL) posted its quarterly earnings results on Tuesday, February, 7th. The biotechnology company reported ($0.17) EPS for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. What ETFs hold Anavex Life Sciences' stock? ETFs with the largest weight of Anavex Life Sciences (NASDAQ:AVXL) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Biotech ETF (XBI), ALPS Medical Breakthroughs ETF (SBIO), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), Invesco Nasdaq Biotechnology ETF (IBBQ) and iShares Biotechnology ETF (IBB). What other stocks do shareholders of Anavex Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Anavex Life Sciences investors own include Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE) and OPKO Health (OPK). What is Anavex Life Sciences' stock symbol? Anavex Life Sciences trades on the NASDAQ under the ticker symbol "AVXL." Who are Anavex Life Sciences' major shareholders? Anavex Life Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include Geode Capital Management LLC (1.80%), Silverarc Capital Management LLC (0.00%), Millennium Management LLC (1.07%), Susquehanna International Group LLP (0.00%), Charles Schwab Investment Management Inc. (0.72%) and Morgan Stanley (0.49%). Insiders that own company stock include Athanasios Skarpelos, Elliot Favus, Elliot Favus, Peter DO Donhauser and Sandra Boenisch. View institutional ownership trends. How do I buy shares of Anavex Life Sciences? Shares of AVXL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Anavex Life Sciences' stock price today? One share of AVXL stock can currently be purchased for approximately $8.72. How much money does Anavex Life Sciences make? Anavex Life Sciences (NASDAQ:AVXL) has a market capitalization of $680.42 million. The biotechnology company earns $-47,980,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis. How can I contact Anavex Life Sciences? Anavex Life Sciences' mailing address is 51 W 52ND STREET 7TH FLOOR, NEW YORK NY, 10019. The official website for the company is www.anavex.com. The biotechnology company can be reached via phone at (844) 689-3939 or via email at ir@anavex.com. This page (NASDAQ:AVXL) was last updated on 3/25/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.